EU Reviews Gilenya on Concern Over Effects on Heart

EU Reviews Gilenya on Concern Over Effects on Heart

Novartis AG via Bloomberg

The European Medicines Agency started a review of Novartis AG’s Gilenya pill for multiple sclerosis.